摘要
目的:探讨盐酸沙格雷酯应用于股腘动脉长段闭塞性病变腔内治疗术后,抗凝的疗效和安全性。方法:对我院2010年07月至2011年12月,行下肢股腘动脉长段闭塞性病变腔内治疗术共97例。依据术后是否应用盐酸沙格雷酯联合抗血小板、预防血栓形成用药分为两组进行回顾性对照研究,其中研究组(沙格雷酯+阿司匹林、氯吡格雷)53例,对照组(阿司匹林、氯吡格雷)44例。对介入治疗术后血管通畅率、再狭窄率对比分析。并对研究组药物不良反应及出血事件进行临床安全性分析。结果:研究组及对照组术后3个月、6个月及1年通畅率分别为96.2%/93.1%,94.3%/93.1%,92.5%/88.6%;术后3个月、6个月及1年再狭窄率9.4%/9.1%,13.2%/18.2%,15.1%/18.2%,两组比较差异无统计学意义(P>0.05)。临床安全性分析,研究组出现1例出血事件(2.5%),未见药物不良反应。结论:盐酸沙格雷酯联合阿司匹林、氯吡格雷用于股腘动脉长段闭塞病变介入治疗,术后经抗血小板治疗、预防闭塞及再狭窄发生安全有效。
Objective：To evaluate the Clinical outcome and security analysis of retrospective study of sarpogrelate hydrochloride using in postoperative anticoagulation of endovascular treatment for extensive chronic SFA and popliteal arterial occlusions.Methods： From July 2010 to December 2011,a total of 97 limbs of extensive chronic SFA and popliteal arterial occlusions that received the endovascular treatment,randomized designed to two groups,sarpogrelate hydrochloride was used with aspirin and clopidogrel for postoperative anticoagulation the study group（53 limbs） in study group,venus control group（44 limbs） without using sarpogrelate hydrochloride,compared the patency rate and restenotic rate from the two groups.And made the security analysis for the study group.Results： The 3-months,6-months and 1-year patency of SFA and popliteal artery in study group and contral group were 96.2% / 93.1%,94.3%/93.1%,92.5%/88.6% respectively.The 3-months,6-months and 1-year restenotic rate of SFA and popliteal artery in study group and contral group were 9.4%/9.1%,13.2%/18.2%,15.1%/18.2%,respectively.No statistically significant difference between two groups（P0.05）.There was one bleeding event in study group（2.5%）,no adverse drug event.Conclusion： Sarpogrelate hydrochloride was used with aspirin and clopidogrel for postoperative anticoagulation after endovascular treatment for extensive chronic SFA and popliteal arterial occlusions is effective and safe.
出处
《心肺血管病杂志》
CAS
2013年第1期7-9,共3页
Journal of Cardiovascular and Pulmonary Diseases
关键词
盐酸沙格雷酯
股腘动脉长段闭塞病变
抗凝
Sarpogrelate hydrochloride
Extensive chronic SFA and popliteal arterial occlusion
Anticoagulation
